Adalimumab-adbm injection, a biosimilar to Humira ® (adalimumab), has been made available by Boehringer Ingelheim. Adalimumab-adbm injection is an interchangeable biosimilar and can be substituted for ...

As widely expected by the pharmaceutical industry, seven pharmaceutical companies are releasing biosimilars of AbbVie's Humira. Boehringer Ingelheim's Cyltezo (adalimumab-adbm), an interchangeable ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial) of ...

The Food and Drug Administration has granted an expanded interchangeable designation for Celltrion’s Yuflyma (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) ...

June 27, 2006 — The US Food and Drug Administration (FDA) has approved a pill-swallowing cup to facilitate ingestion of medications and vitamins in patients who have difficulty swallowing; an ...

Humira (adalimumab) is a prescription drug that’s used to treat certain types of arthritis and other inflammation-related diseases. It comes as a liquid solution for injection under your skin. Humira ...

Medically reviewed by Shadi Hamdeh, MDMedically reviewed by Shadi Hamdeh, MD Humira (adalimumab) side effects may include pain, irritation, swelling, or itching at the site of the injection, as well ...

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor. Starting July 1, alternatives to the ...

Humira (adalimumab) is a prescription drug used for various conditions, including rheumatoid arthritis and plaque psoriasis. Mild side effects of the drug include injection site reactions, headache, ...

AbbVie GK, Eisai Co. and EA Pharma Co. have debuted the HUMIRA Pen, an auto-injector pen meant to help simplify self-injection. The product, which has a rounded pen-type body designed to help patients ...

Tennessee last year spent $48 million on a single drug, Humira — about $62,000 for each of the 775 patients who were covered by its employee health insurance program and receiving the treatment. So ...